Interventions against mixed chimerism
| Intervention . | Total (n = 103) . | Lowest DC ≤30% (n = 56) . | DC always >30% (n = 47) . | P value . |
|---|---|---|---|---|
| Second HSCT for HLH recurrence, n (% of column) | 10 (10%) | 10 (18%) | ||
| Days after first HSCT, median (range) | 372 (69-2721) | 372 (69-2721) | ||
| Median overall DC, %, median (range) | 7 (0-18) | 7 (0-18) | ||
| Median CD3+ DC, %, median (range) | 10 (0-18) | 10 (0-18) | ||
| Second HSCT for low DC, n (% of column) | 8 (8%) | 8 (14%) | ||
| Days after first HSCT, median (range) | 294 (167-1797) | 294 (167-1797) | ||
| Median overall DC, %, median (range) | 3 (0-19) | 3 (0-19) | ||
| Median CD3+ DC, %, median (range) | 7 (0-30) | 7 (0-30) | ||
| DLI (first application), n (% of column) | 59 (57%) | 41 (73%) | 18 (38%) | .0006 |
| Days after first HSCT, median (range) | 121 (29-955) | 112 (29-431) | 149 (44-955) | .0228 |
| Median overall DC, %, median (range) | 46 (0-97) | 30 (0-97) | 58 (36-92) | .0034 |
| Median CD3+ DC, %, median (range) | 41 (0-98) | 30 (0-85) | 90 (41-98) | .0194 |
| Stem cell boost (first application), n (% of column) | 14 (14%) | 12 (21%) | 2 (4%) | .0185 |
| Days after first HSCT, median (range) | 167 (36-815) | 184 (36-815) | (57-151) | |
| Median overall DC, %, median (range) | 43% (1-99) | 32 (1-99) | (71-97) | |
| Median CD3+ DC, %, median (range) | 40% (10-65) | 40 (10-65) | NA | |
| Weaning of immune suppression, n (% of column) | 65 (63%) | 44 (79%) | 21 (45%) | .0005 |
| Days after first HSCT, median (range) | 55 (16-593) | 45 (16-593) | 76 (23-124) | .0149 |
| Median overall DC, %, median (range) | 85 (9-98) | 85 (9-98) | 89 (32-98) | .0779 |
| Median CD3+ DC, %, median (range) | NA | NA | NA |
| Intervention . | Total (n = 103) . | Lowest DC ≤30% (n = 56) . | DC always >30% (n = 47) . | P value . |
|---|---|---|---|---|
| Second HSCT for HLH recurrence, n (% of column) | 10 (10%) | 10 (18%) | ||
| Days after first HSCT, median (range) | 372 (69-2721) | 372 (69-2721) | ||
| Median overall DC, %, median (range) | 7 (0-18) | 7 (0-18) | ||
| Median CD3+ DC, %, median (range) | 10 (0-18) | 10 (0-18) | ||
| Second HSCT for low DC, n (% of column) | 8 (8%) | 8 (14%) | ||
| Days after first HSCT, median (range) | 294 (167-1797) | 294 (167-1797) | ||
| Median overall DC, %, median (range) | 3 (0-19) | 3 (0-19) | ||
| Median CD3+ DC, %, median (range) | 7 (0-30) | 7 (0-30) | ||
| DLI (first application), n (% of column) | 59 (57%) | 41 (73%) | 18 (38%) | .0006 |
| Days after first HSCT, median (range) | 121 (29-955) | 112 (29-431) | 149 (44-955) | .0228 |
| Median overall DC, %, median (range) | 46 (0-97) | 30 (0-97) | 58 (36-92) | .0034 |
| Median CD3+ DC, %, median (range) | 41 (0-98) | 30 (0-85) | 90 (41-98) | .0194 |
| Stem cell boost (first application), n (% of column) | 14 (14%) | 12 (21%) | 2 (4%) | .0185 |
| Days after first HSCT, median (range) | 167 (36-815) | 184 (36-815) | (57-151) | |
| Median overall DC, %, median (range) | 43% (1-99) | 32 (1-99) | (71-97) | |
| Median CD3+ DC, %, median (range) | 40% (10-65) | 40 (10-65) | NA | |
| Weaning of immune suppression, n (% of column) | 65 (63%) | 44 (79%) | 21 (45%) | .0005 |
| Days after first HSCT, median (range) | 55 (16-593) | 45 (16-593) | 76 (23-124) | .0149 |
| Median overall DC, %, median (range) | 85 (9-98) | 85 (9-98) | 89 (32-98) | .0779 |
| Median CD3+ DC, %, median (range) | NA | NA | NA |
Interventions were compared between patients in whom DC was always >30% and patients in whom the lowest DC level was ≤30%. Interventions were not only more frequent in the DC ≤30% group. They were performed sooner after HSCT; however, at an already lower level of DC. Availabilities of CD3+ DC levels at weaning of immune suppression and CD56+ DC levels in general were not insufficient to allow for comparisons. Details on each secondary HSCT are listed in supplemental Table 2.